An APACHE-II-score ≥ 24 on the 1 po day is a prospectively validated parameter to identify cardiac surgery patients with an escalating \`post pump\' systemic inflammatory response syndrome at high risk of multiple organ dysfunction syndrome. We investigated the impact of cardiopulmonary bypass-assisted cardiac surgery on monocyte markers in a prospectively conducted study for up to 5 days (group 1: APACHE II ≥ 24, group 2: APACHE II \<24), compared to septic non-surgical patients (Elebute sepsis score ≥ 12, APACHE II score ≥ 24).

Results
=======

HLA-DR: significant fall from day 0 to day 1 (*P* \< 0.05; generalised linear model), but no significant difference between groups 1 and 2; CD 86: no significant differences.

Mean channel fluorescence (FACS^®^) ± SD, corrected by isotype control:

Conclusion
==========

The expression of HLA-DR and CD86 on monocytes does not allow for an early risk stratification after cardiac surgery.

  HLA-DR            Day 0                     Day 1                    Day 5
  ----------------- ------------------------- ------------------------ --------------------------
  Group 1             1060 ± 505 (*n* = 24)     403 ± 186 (*n* = 24)     500 ± 298 (*n* = 23)
  Group 2           1099 ± 525 (*n* = 5)      380 ± 158 (*n* = 5)      472 ± 182 (*n* = 2)
  Group 3                                     483 ± 360 (*n* = 8)      332 ± 130 (*n* = 7)
  CD 86                                                                
  (costimulatory)   Day 0                     Day 1                    Day 5
                                                                       
  Group 1             380 ± 325 (*n* = 24)      353 ± 520 (*n* = 24)       392 ± 439 (*n* = 23)
  Group 2           630 ± 773 (*n* = 5)       287 ± 205 (*n* = 5)      405 ± 98 (*n* = 2)
  Group 3                                     618 ± 746 (*n* = 8)        243 ± 175 (*n* = 7)
